Concepedia

Jonathan Haddad

JH

8

Publications

638

Citations

8

H-Index

2002

Active since

Affiliations

Tris Pharma (United States)(Current)

GlaxoSmithKline (United States)

Research Triangle Park Foundation

Jonathan Haddad is an author at Tris Pharma (United States) specializing in risk management, management, and pharmacology.

Top concepts

Publications per year

2002–2018

8

Publications

8

Phase II, Randomized, Controlled, Double-Blinded Trial of Weekly Elesclomol Plus Paclitaxel Versus Paclitaxel Alone for Stage IV Metastatic Melanoma

Steven O’Day, René González, David H. Lawson et al. · Journal of Clinical Oncology · 2009 · 196 citations · Full text

A Pilot Randomized, Placebo Controlled, Double Blind Phase I Trial of the Novel SIRT1 Activator SRT2104 in Elderly Volunteers

Vincenzo Libri, Andrew Brown, Giulio Gambarota et al. · PLoS ONE · 2012 · 123 citations · Full text

A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis

James G. Krueger, Mayte Suárez‐Fariñas, Inna Cueto et al. · PLoS ONE · 2015 · 99 citations · Full text

A phase <scp>II</scp>, randomized, placebo‐controlled, double‐blind, multi‐dose study of <scp>SRT2104</scp>, a <scp>SIRT1</scp> activator, in subjects with type 2 diabetes

A Baksi, O. V. Kraydashenko, Alsu Zalevkaya et al. · British Journal of Clinical Pharmacology · 2014 · 80 citations · Full text

Christmas, national holidays, sport events, and time factors as triggers of acute myocardial infarction: SWEDEHEART observational study 1998-2013

Moman A. Mohammad, Sofia Karlsson, Jonathan Haddad et al. · BMJ · 2018 · 57 citations · Full text

Rows per page

1–5 of 8